Pharmacoeconomic review report : Cladribine (Mavenclad) (EMD Serono) : indication : as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Drugs--Cost effectiveness.

Drugs.

Physical Description:

1 online resource.

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2018.

Summary:

Cladribine (Mavenclad) is indicated as monotherapy for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and delay the progression of disability. It is administered orally and is available as a 10 mg tablet at a price of 3,082.70 dollars per tablet. The recommended cumulative dose is 3.5 mg/kg over the course of two years, with one treatment course of 1.75 mg/kg per year. The treatment course is spread over two weeks each year, one week at the beginning of the first month of that year, and the other at the beginning of the second month. During each week, patients receive one or two 10 mg tablets, based on body weight, over the course of four to five days. The average annual cost is 43,158 dollars based on patient weight of 70 kg. The manufacturer submitted a cost-utility analysis based on a Markov state-transition model comparing cladribine with other available disease-modifying therapies (DMTs).

Contents:

Abbreviations

Executive Summary

Background

Summary of Identified Limitations and Key Results

Conclusions

Information on the Pharmacoeconomic Submission

Summary of the Manufacturer's Pharmacoeconomic Submission

Manufacturer's Base Case

Summary of Manufacturer's Sensitivity Analyses

Limitations of Manufacturer's Submission

CADTH Common Drug Review Reanalyses

Issues for Consideration

Patient Input

Appendix 1. Cost Comparison

Appendix 2. Additional Information

Appendix 3. Summary of Other HTA Reviews of Drug

Appendix 4. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.